| Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors E Liu, D Marin, P Banerjee, HA Macapinlac, P Thompson, R Basar, ... New England Journal of Medicine 382 (6), 545-553, 2020 | 1584 | 2020 |
| Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for … RG Maki, JK Wathen, SR Patel, DA Priebat, SH Okuno, B Samuels, ... Journal of Clinical Oncology 25 (19), 2755-2763, 2007 | 848 | 2007 |
| Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell … S Giralt, PF Thall, I Khouri, X Wang, I Braunschweig, C Ippolitti, D Claxton, ... Blood, The Journal of the American Society of Hematology 97 (3), 631-637, 2001 | 703 | 2001 |
| Some covariance models for longitudinal count data with overdispersion PF Thall, SC Vail Biometrics, 657-671, 1990 | 622 | 1990 |
| Dose-finding based on efficacy–toxicity trade-offs PF Thall, JD Cook Biometrics 60 (3), 684-693, 2004 | 549 | 2004 |
| Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a … M De Lima, S Giralt, PF Thall, L de Padua Silva, RB Jones, K Komanduri, ... Cancer 116 (23), 5420-5431, 2010 | 483 | 2010 |
| Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell … M De Lima, D Couriel, PF Thall, X Wang, T Madden, R Jones, EJ Shpall, ... Blood 104 (3), 857-864, 2004 | 482 | 2004 |
| Platinum-based chemotherapy for variant castrate-resistant prostate cancer AM Aparicio, AL Harzstark, PG Corn, S Wen, JC Araujo, SM Tu, ... Clinical cancer research 19 (13), 3621-3630, 2013 | 451 | 2013 |
| Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study LC Pagliaro, DL Williams, D Daliani, MB Williams, W Osai, M Kincaid, ... Journal of Clinical Oncology 28 (24), 3851-3857, 2010 | 374 | 2010 |
| Bayesian sequential monitoring designs for single‐arm clinical trials with multiple outcomes PF Thall, RM Simon, EH Estey Statistics in medicine 14 (4), 357-379, 1995 | 349 | 1995 |
| Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or … E Estey, P Thall, M Andreeff, M Beran, H Kantarjian, S O'Brien, S Escudier, ... Journal of Clinical Oncology 12 (4), 671-678, 1994 | 333 | 1994 |
| A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials PF Thall, KE Russell Biometrics, 251-264, 1998 | 319 | 1998 |
| Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer SH Lin, L Wang, B Myles, PF Thall, WL Hofstetter, SG Swisher, JA Ajani, ... International Journal of Radiation Oncology* Biology* Physics 84 (5), 1078-1085, 2012 | 309 | 2012 |
| High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation SO Ciurea, M De Lima, P Cano, M Korbling, S Giralt, EJ Shpall, X Wang, ... Transplantation 88 (8), 1019-1024, 2009 | 307 | 2009 |
| Prognostic significance of preoperative MRI scans in glioblastoma multiforme MA Hammoud, R Sawaya, W Shi, PF Thall, NE Leeds Journal of neuro-oncology 27, 65-73, 1996 | 305 | 1996 |
| Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate CN Papandreou, DD Daliani, PF Thall, SM Tu, X Wang, A Reyes, ... Journal of clinical oncology 20 (14), 3072-3080, 2002 | 298 | 2002 |
| Determining the effective sample size of a parametric prior S Morita, PF Thall, P Müller Biometrics 64 (2), 595-602, 2008 | 297 | 2008 |
| Randomized phase II study of fludarabine+ cytosine arabinoside+ idarubicin±all-trans retinoic acid±granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute … EH Estey, PF Thall, S Pierce, J Cortes, M Beran, H Kantarjian, MJ Keating, ... Blood, The Journal of the American Society of Hematology 93 (8), 2478-2484, 1999 | 285 | 1999 |
| Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using … CG Kanakry, PV O'Donnell, T Furlong, MJ De Lima, W Wei, M Medeot, ... Journal of Clinical Oncology 32 (31), 3497-3505, 2014 | 275 | 2014 |
| Practical Bayesian guidelines for phase IIB clinical trials PF Thall, R Simon Biometrics, 337-349, 1994 | 274 | 1994 |
